Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar in kidney transplant patients
NCT01694160Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Jan 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paricalcitol oral solution in proteinuria (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Albumin/Creatinine Ratio at 1 year. Started Jan 2013; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
proteinuria
Beyond the preview
Go deeper on NCT01694160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01694160.